Biomea Fusion (NASDAQ:BMEA) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Posted by Stanley Muller on May 11th, 2026

Biomea Fusion (NASDAQ:BMEA – Get Free Report) issued its earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.07, FiscalAI reports.

Biomea Fusion Stock Performance

Biomea Fusion stock traded up $0.03 during trading hours on Monday, reaching $1.57. 1,556,933 shares of the stock were exchanged, compared to its average volume of 1,419,342. The stock has a market cap of $113.51 million, a P/E ratio of -1.20 and a beta of -0.32. Biomea Fusion has a 52-week low of $0.87 and a 52-week high of $3.08. The firm’s 50 day moving average is $1.54 and its 200 day moving average is $1.38.

Hedge Funds Weigh In On Biomea Fusion

A number of large investors have recently bought and sold shares of BMEA. Marshall Wace LLP raised its position in Biomea Fusion by 293.7% during the 4th quarter. Marshall Wace LLP now owns 1,160,351 shares of the company’s stock worth $1,439,000 after buying an additional 865,618 shares during the last quarter. Mariner LLC raised its position in Biomea Fusion by 145.1% during the 4th quarter. Mariner LLC now owns 585,632 shares of the company’s stock worth $726,000 after buying an additional 346,702 shares during the last quarter. Vanguard Group Inc. raised its position in Biomea Fusion by 15.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,170,066 shares of the company’s stock worth $4,384,000 after buying an additional 290,376 shares during the last quarter. AQR Capital Management LLC raised its position in Biomea Fusion by 670.5% during the 1st quarter. AQR Capital Management LLC now owns 264,028 shares of the company’s stock worth $562,000 after buying an additional 229,763 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in Biomea Fusion by 61.0% during the 3rd quarter. Two Sigma Investments LP now owns 562,968 shares of the company’s stock worth $1,137,000 after buying an additional 213,321 shares during the last quarter. Hedge funds and other institutional investors own 96.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Citizens Jmp assumed coverage on shares of Biomea Fusion in a report on Tuesday, May 5th. They issued a “market outperform” rating and a $9.00 target price for the company. Citigroup started coverage on shares of Biomea Fusion in a research note on Tuesday, May 5th. They set an “outperform” rating for the company. D. Boral Capital reiterated a “buy” rating and set a $12.00 price target on shares of Biomea Fusion in a research note on Tuesday, April 28th. Wall Street Zen upgraded shares of Biomea Fusion from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biomea Fusion in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Biomea Fusion presently has an average rating of “Moderate Buy” and a consensus price target of $8.29.

Read Our Latest Analysis on Biomea Fusion

About Biomea Fusion

(Get Free Report)

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.

Earnings History for Biomea Fusion (NASDAQ:BMEA)

Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.